Everolimus in Postmenopausal, Hormone Receptor-Positive Advanced Breast Cancer: Summary and Results of an Austrian Expert Panel Discussion
暂无分享,去创建一个
R. Greil | M. Gnant | G. Steger | M. Hubalek
[1] M. Piccart,et al. Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. , 2013, Journal of the National Cancer Institute.
[2] G. Hortobagyi,et al. Effects of everolimus (EVE) on disease progression in bone and bone markers (BMs) in patients (pts) with bone metastases (mets). , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] I. Ray-Coquard,et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. Buyse,et al. BOLERO-1: A randomized, phase III, double-blind, placebo-controlled multicenter trial of everolimus in combination with trastuzumab and paclitaxel as first-line therapy in women with HER2-positive (HER2+), locally advanced or metastatic breast cancer (BC). , 2012 .
[5] G. Hortobagyi,et al. Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.
[7] P. Soares,et al. The mTOR Signalling Pathway in Human Cancer , 2012, International journal of molecular sciences.
[8] M. Piccart,et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. , 2012, The New England journal of medicine.
[9] M. Piccart,et al. S3-7: Everolimus for Postmenopausal Women with Advanced Breast Cancer: Updated Results of the BOLERO-2 Phase III Trial. , 2011 .
[10] H. Burstein. Novel agents and future directions for refractory breast cancer. , 2011, Seminars in oncology.
[11] G. Mills,et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. , 2010, The Journal of clinical investigation.
[12] M. Holz,et al. mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor α serine 167 phosphorylation , 2010, FEBS letters.
[13] R. Greil,et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] M. Holz,et al. S6 Kinase 1 Regulates Estrogen Receptor α in Control of Breast Cancer Cell Proliferation* , 2009, Journal of Biological Chemistry.
[15] M. Stockler,et al. Third consensus on medical treatment of metastatic breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] M. Holz,et al. S6 Kinase 1 Regulates Estrogen Receptor (cid:1) in Control of Breast Cancer Cell Proliferation * , 2009 .
[17] Ji-ping Wang,et al. Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells , 2007, The Journal of Steroid Biochemistry and Molecular Biology.
[18] M. Beeram,et al. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] M. Stockler,et al. Second consensus on medical treatment of metastatic breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] P. Goss,et al. Estrogen Receptor Pathway: Resistance to Endocrine Therapy and New Therapeutic Approaches , 2006, Clinical Cancer Research.
[21] S. Johnston. Clinical Efforts to Combine Endocrine Agents with Targeted Therapies against Epidermal Growth Factor Receptor/Human Epidermal Growth Factor Receptor 2 and Mammalian Target of Rapamycin in Breast Cancer , 2006, Clinical Cancer Research.
[22] Shiuan Chen,et al. Dual Inhibition of mTOR and Estrogen Receptor Signaling In vitro Induces Cell Death in Models of Breast Cancer , 2005, Clinical Cancer Research.
[23] R. Kumar,et al. Adaptive hypersensitivity to estrogen: Mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment , 2005, The Journal of Steroid Biochemistry and Molecular Biology.
[24] Manuel Hidalgo,et al. Inhibition of mTOR Activity Restores Tamoxifen Response in Breast Cancer Cells with Aberrant Akt Activity , 2004, Clinical Cancer Research.
[25] H. Lane,et al. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts. , 2004, Bone.
[26] Jiang Shou,et al. Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance , 2004, Clinical Cancer Research.
[27] G. Wesolowski,et al. M-CSF, TNFα and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase , 2003, Cell Death and Differentiation.